OPKO Health Inc

OPKO Health Inc. a healthcare company engages in the diagnostics and pharmaceuticals businesses in the United States Ireland Chile Spain Israel Mexico and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection diagnosis evaluation monitoring and treatment of diseases including esoteric testing molecular diagnostics anatomical pathology genetics women's health and correctional healthcare to physician offices clinics hospitals employers and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology infectious diseases vaccines and immunology; OPK88004 an orally administered selective androgen receptor modulator; OPK88003 a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP) a once-weekly human growth hormone injection; and Factor VIIa-CTP a novel long-acting coagulation factor being developed to treat hemophilia. In addition it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops manufactures markets and sells pharmaceutical nutraceutical veterinary and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets distributes and sells pharmaceutical products in a range of indications including cardiovascular products vaccines antibiotics gastro-intestinal products hormones and others. The company also operates pharmaceutical platforms in Ireland Chile Spain and Mexico. The company was founded in 1991 and is headquartered in Miami Florida.